Table 1.
Intersection of transcriptome meta-analysis and GWAS investigations for MDD, comorbid disorders and other disorders and traits
| Categories | Studies, n | 20 kb |
50 kb |
100 kb |
200 kb |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| p value | genes, n | metaA-MDD genes, n | p value | genes, n | metaA-MDD genes, n | p value | genes, n | metaA-MDD genes, n | p value | genes, n | metaA-MDD genes, n | ||
| Neurological disorders and other brain phenotypes | 221 | 0.065 | 1,453 | 53 | 0.032 | 1,823 | 60 | 0.023 | 2,168 | 70 | 0.032 | 2,483 | 75 |
| Neuropsychiatric disorders | 97 | 0.021 | 720 | 31 | 0.007 | 913 | 35 | 0.006 | 1,106 | 42 | 0.010 | 1,267 | 42 |
| MDD-related disorders | 22 | 0.199 | 273 | 9 | 0.214 | 338 | 10 | 0.304 | 415 | 11 | 0.248 | 489 | 13 |
| Aging | 30 | 0.030 | 215 | 14 | 0.007 | 271 | 17 | 0.007 | 321 | 18 | 0.008 | 360 | 19 |
| Medical illnesses related to MDD | 315 | 0.214 | 2,608 | 89 | 0.163 | 3,198 | 98 | 0.298 | 3,676 | 103 | 0.285 | 4,060 | 115 |
| Cardiovascular diseases and related traits | 113 | 0.545 | 762 | 21 | 0.516 | 961 | 26 | 0.597 | 1,125 | 30 | 0.681 | 1,264 | 33 |
| Metabolic syndrome and related traits | 98 | 0.272 | 1,281 | 43 | 0.143 | 1,566 | 49 | 0.265 | 1,802 | 52 | 0.131 | 2,034 | 61 |
| Immune system, inflammation | 94 | 0.601 | 847 | 33 | 0.733 | 1,028 | 34 | 0.795 | 1,207 | 38 | 0.825 | 1,336 | 40 |
| Other medical illnesses not related to MDD | 444 | 0.825 | 2,264 | 78 | 0.870 | 2,685 | 85 | 0.745 | 3,076 | 97 | 0.747 | 3,419 | 98 |
| Cancer | 110 | 0.96 | 549 | 15 | 0.975 | 660 | 16 | 0.878 | 771 | 23 | 0.829 | 879 | 26 |
| Miscellaneous body measures | 230 | 0.567 | 1,309 | 45 | 0.708 | 1,569 | 46 | 0.723 | 1,812 | 52 | 0.782 | 2,027 | 51 |
| (Neurological disorders) – (neuropsychiatric disorders) | 118 | 0.550 | 792 | 24 | 0.596 | 995 | 28 | 0.508 | 1,185 | 33 | 0.473 | 1,373 | 38 |
| (Aging) – (neuropsychiatric disorders) | 27 | 0.016 | 213 | 14 | 0.009 | 269 | 17 | 0.010 | 319 | 18 | 0.009 | 358 | 19 |
Genes identified nearby significant genetic variants in each GWAS (at p < 1 × 10–5) of the ~1,800 studies in the GWAS Catalog were sorted into categories based on clinical evidence for comorbidity (or not) with MDD, and the significance of overlap with metaA-MDD genes was calculated for each category. The table includes the number of studies in the respective category as well as the p value of the significance for the overrepresentation of the metaA-MDD genes compared to the total number of genes in that category. In the bottom two analyses, GWAS related to both categories were removed. Results from the ‘aging’ category are not due to overlap in gene content with neuropsychiatry-related genes, whereas the ‘neurological disorders and other brain phenotypes’ category results are driven by neuropsychiatry-related genes. The results are presented for four genomic windows represented by the distance of genes from GWAS SNPs (numbers at the top of the table). Values in italics indicate significant results. Gene categories in boldface are significant.